{"id":2229753,"date":"2026-09-29T15:41:41","date_gmt":"2026-09-29T13:41:41","guid":{"rendered":"https:\/\/kohenavocats.com\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/"},"modified":"2026-09-29T16:22:02","modified_gmt":"2026-09-29T14:22:02","slug":"blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026","status":"publish","type":"post","link":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/","title":{"rendered":"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France"},"content":{"rendered":"<p>On 17 September 2026, the United States Food and Drug Administration classified as Class II the nationwide recall of 13,567 bottles of chlorthalidone 25 mg tablets that may not dissolve properly in the body. If you take a blood pressure medicine containing chlortalidone, if you bought boxes in the United States, or if a relative living across the Atlantic sent you this alert, one question matters: are your tablets affected, and what does French and European law give you when a medicine turns out to be defective? This article starts from the American recall file, as reported by the American press on 28 and 29 September 2026, and explains the French answer point by point: how to check whether a box sold in France is concerned, how the French medicines agency (Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9, ANSM) handles batch withdrawals and recalls (retraits et rappels de lots), how to file an adverse-event report (signalement) in France, and on which legal grounds you can claim compensation from the producer of a <a href=\"https:\/\/kohenavocats.com\/en\/medical-negligence-lawyer-paris\/\">defective medicine<\/a> before the French courts, within a three-year limitation period and with the help of European case law that lowers the burden of proof for patients.<\/p>\n<h2>I. Is my blood pressure medication recalled?<\/h2>\n<h3>A. Which chlorthalidone tablets did the FDA recall?<\/h3>\n<p>According to the enforcement file published by the Food and Drug Administration under event number 99806, the recall concerns one precisely identified product: Chlorthalidone Tablets, USP, 25 mg, 100 tablets per bottle, prescription only, manufactured by Inventia Healthcare Limited, NDC 64980-599-01, batch RISA24002, expiry 04\/2027, 13,567 bottles, reason stated as failed dissolution specifications (FDA enforcement file, event 99806). The file adds that the recall was initiated by the firm itself on 3 September 2026, that consignees were notified by letter, that distribution was nationwide across the United States, and that the classification was raised from unclassified to Class II on 17 September 2026. The American press relayed the measure immediately: USA Today published a nationwide alert on 29 September 2026 listing the affected medicine, and the business press reported that the same manufacturer was already recalling chlorthalidone tablets a second time this year, with figures of 25,000 bottles mentioned for the earlier operation. These press reports describe a dissolution failure, which means, in plain terms, that the tablet may not release its active ingredient as the marketing authorisation requires, so the body may absorb less medicine than the label promises.<\/p>\n<p>For a patient treated for hypertension, that technical detail has a concrete meaning. Chlorthalidone is a thiazide-like diuretic prescribed to lower blood pressure and thereby reduce the risk of stroke, heart attack and heart failure. A tablet that dissolves badly is not a tablet that poisons; it is a tablet that may under-treat. Blood pressure can climb back silently while the patient believes they are protected, and the cardiovascular events that follow weeks or months later are then difficult to connect with the defective batch. That is exactly why the applicable French and European rules treat the lack of therapeutic effect as a defect in itself: Article 116 of Directive 2001\/83\/EC on the Community code for medicinal products (CELEX:32001L0083) provides, in its French version, that a marketing authorisation is suspended or withdrawn where \u00ab l&#8217;effet th\u00e9rapeutique fait d\u00e9faut \u00bb (therapeutic efficacy is lacking). A batch that fails dissolution specifications is the textbook example of a product whose therapeutic effect is lacking, and the recall, even classified Class II rather than Class I, confirms that the authorities regard the risk as real enough to pull more than thirteen thousand bottles from pharmacies and wholesalers.<\/p>\n<p>Two reservations must be stated clearly at this stage, because they frame everything that follows. First, at the date of writing, no accident, no hospitalisation and no bodily injury linked to batch RISA24002 has been established by an official source; the FDA file describes a quality failure and a preventive withdrawal, not a list of victims. Second, no liability has been established against any company: the recall was initiated voluntarily by the firm, and only a court, applying the rules explained below, can decide whether a defect caused a compensable loss. With those limits in mind, the useful question for a reader in France is the next one: the recalled bottles were distributed in the United States, but the same molecule is prescribed on both sides of the Atlantic, so what is the situation of boxes dispensed in France?<\/p>\n<h3>B. Is chlorthalidone sold in France?<\/h3>\n<p>Yes. The active ingredient chlorthalidone, spelled chlortalidone in French, is present in medicines marketed in France today. The public medicines database maintained under the responsibility of the ANSM lists <a href=\"https:\/\/base-donnees-publique.medicaments.gouv.fr\/medicament\/62980497\/extrait\">TENORETIC 50 mg\/12.5 mg film-coated tablets, a fixed combination of atenolol and chlortalidone indicated in arterial hypertension<\/a>, with current reimbursed prices displayed, which confirms that boxes containing this diuretic are dispensed in French pharmacies right now. An older single-ingredient brand, HYGROTON 25 mg tablets, appears in the ANSM directory of pharmaceutical specialties, but its marketing authorisation is archived since 7 May 2011 after marketing stopped on 19 May 2000, as shown on its directory record in the ANSM repertoire of pharmaceutical specialties. The practical consequence is simple: a patient treated in France with a chlortalidone-containing medicine almost certainly holds TENORETIC or a product of the same family, not the American bottles identified by the FDA, because the recalled batch, NDC 64980-599-01, was distributed on the American market by an Indian manufacturer whose product has no French marketing authorisation under that reference.<\/p>\n<p>Three groups of readers should still pay attention. The first group is made of people who travel: a French resident who filled a prescription in the United States, an American expatriate living in France who brought their treatment with them, and a student or worker returning from across the Atlantic with a few months of tablets in their luggage. If the box shows NDC 64980-599-01, batch RISA24002 and expiry 04\/2027, it belongs to the recalled population wherever it physically sits, including on a shelf in Paris, Lyon or Marseille, and the American recall notice applies to it directly. The second group is made of patients treated in France with TENORETIC or another chlortalidone-based medicine who now wonder whether the American failure reveals a problem with the molecule itself. The answer is reassuring but conditional: dissolution is a property of each manufacturer&#8217;s own formulation and each production batch, not of the molecule in the abstract, so a manufacturing failure at one Indian plant says nothing, by itself, about tablets made by another company for the French market. The third group is made of patients who experienced an unexplained rebound of their blood pressure while taking any chlortalidone-based treatment in recent months; for them, the American case is a reminder that a batch failure is a hypothesis worth checking with their doctor and pharmacist, by reading the batch number printed on the box and by asking whether the ANSM has published any batch withdrawal (retrait de lot) for their own brand.<\/p>\n<p>France has already lived through this exact scenario with another blood pressure family, and the precedent shows how Paris reacts when lots are defective. In December 2018, the ANSM published a valsartan recall notice explaining that, after a first wave of withdrawals at the end of November concerning two manufacturers, <a href=\"https:\/\/ansm.sante.fr\/actualites\/rappel-de-valsartan-lansm-rappelle-la-conduite-a-tenir-dans-un-contexte-de-fortes-tensions-dapprovisionnement\">\u00ab un nouveau rappel de 64 lots \u00bb<\/a> (a further recall of 64 batches), carried out as a precaution on all batches of one laboratory, about 6% of the French market at the time, after the possible presence of an impurity (NDEA) was identified in those batches. The agency simultaneously circulated instructions to health professionals, kept the remaining stocks for patients with no alternative, and updated the lists of concerned and non-concerned medicines. That is the French method: targeted batch recalls, published lists, professional instructions, and continuity of treatment organised with the doctor rather than brutal interruption. Anyone holding a chlortalidone-based box in France today can apply the same method: read the batch number, search the ANSM safety information pages for the brand name, and ask the dispensing pharmacist, who receives every recall notice through the pharmaceutical supply chain.<\/p>\n<h2>II. What can you do in France after a drug recall?<\/h2>\n<h3>A. How to check your box and report a problem in France<\/h3>\n<p>The first rule is medical before it is legal: never stop a blood pressure treatment on your own initiative because of a press article. Suddenly interrupting a diuretic or a beta-blocker combination can itself provoke a rebound of blood pressure, and the doctor who prescribed the treatment is the only person able to switch the patient to an equivalent brand or molecule without a gap in protection. The correct sequence, the one French pharmacovigilance assumes, runs in four steps. First, take the box and read three lines: the brand name, the batch (lot) number and the expiry date, and photograph them. Second, compare a box bought in the United States with the FDA references: NDC 64980-599-01, batch RISA24002, expiry 04\/2027; if all three match, stop using those tablets, contact the prescriber or pharmacist without delay, and keep the box, the leaflet and the receipt, because the batch number is the evidence that ties the tablets to the official recall file. Third, for a box bought in France, check the ANSM website for a batch withdrawal concerning that exact brand, and ask the pharmacist, who is professionally bound to inform patients when a recall reaches the dispensary. Fourth, if blood pressure readings taken at home show an unexplained rise, or if any unusual symptom appeared while taking the tablets, record the dates, the readings and the batch number in writing, and show that note to the doctor; a dated personal record, kept before any dispute arises, carries real weight later.<\/p>\n<p>The second step is the report (signalement), and French law gives every patient a direct channel. The Code de la sant\u00e9 publique entrusts pharmacovigilance with a broad mission: <a href=\"https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000025086407\">\u00ab La pharmacovigilance a pour objet la surveillance, l&#8217;\u00e9valuation, la pr\u00e9vention et la gestion du risque d&#8217;effet ind\u00e9sirable r\u00e9sultant de l&#8217;utilisation des m\u00e9dicaments \u00bb<\/a> (Pharmacovigilance covers the monitoring, assessment, prevention and management of the risk of adverse effects resulting from the use of medicines). The same code organises reporting in Article R. 5121-161, which provides, in its current version: <a href=\"https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000047950830\">\u00ab Le m\u00e9decin, le chirurgien-dentiste, la sage-femme, le pharmacien ou l&#8217;infirmier d\u00e9clare imm\u00e9diatement tout effet ind\u00e9sirable suspect\u00e9 d&#8217;\u00eatre d\u00fb \u00e0 un m\u00e9dicament [&#8230;], dont il a connaissance, au centre r\u00e9gional de pharmacovigilance. Les autres professionnels de sant\u00e9, les patients et les associations agr\u00e9\u00e9es de patients peuvent d\u00e9clarer tout effet ind\u00e9sirable suspect\u00e9 d&#8217;\u00eatre d\u00fb \u00e0 un m\u00e9dicament [&#8230;], dont ils ont connaissance \u00bb<\/a> (Doctors, dental surgeons, midwives, pharmacists and nurses must immediately report any suspected adverse effect of a medicine of which they are aware to the regional pharmacovigilance centre. Other health professionals, patients and approved patient associations may report any suspected adverse effect of a medicine of which they are aware). In practice, a patient in France reports through the national adverse-event portal (signalement-sante.gouv.fr) or with the help of the pharmacist or doctor, attaching the batch number, the dates of use, the blood pressure readings and any medical document. The report does not itself open a right to compensation, but it feeds the surveillance system that triggers batch withdrawals, and it creates a dated administrative trace of the complaint that a court can later consult.<\/p>\n<p>For readers living in Paris and \u00cele-de-France, two practical points deserve mention. The regional pharmacovigilance centre covering Paris receives the reports filed in the capital, and the hospitals of the region document admissions for hypertensive emergencies with a precision that makes it possible, months later, to reconstruct whether an uncontrolled episode coincided with the use of a given batch. That is why keeping the box matters as much as keeping the medical file: without the batch number, even the best hospital record cannot connect the episode to a manufacturing failure. Comparable American recalls that reached French readers, such as the over-dosed thyroid tablets withdrawn in the United States and <a href=\"https:\/\/kohenavocats.com\/medicament-thyroide-rappel-surdosage-droits-france-2026\/\">explained for patients in France a few days ago<\/a>, followed the same logic of verification first and legal action second. Once the facts are secured, the question becomes legal: against whom, on which ground, and within which time limit can a patient claim compensation in France?<\/p>\n<h3>B. How to claim compensation for a defective medicine in France<\/h3>\n<p>French law answers with a special strict-liability regime for defective products, which applies fully to medicines. Article 1245 of the Civil Code states the principle: <a href=\"https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000032041540\">\u00ab Le producteur est responsable du dommage caus\u00e9 par un d\u00e9faut de son produit, qu&#8217;il soit ou non li\u00e9 par un contrat avec la victime \u00bb<\/a> (The producer is liable for damage caused by a defect in its product, whether or not it is bound by a contract with the victim). The patient therefore sues the manufacturer directly, without needing any contract with the laboratory and without proving negligence: it is enough to establish the defect, the damage and the causal link between them. The defect itself is defined by Article 1245-3: <a href=\"https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000032023633\">\u00ab Un produit est d\u00e9fectueux au sens du pr\u00e9sent chapitre lorsqu&#8217;il n&#8217;offre pas la s\u00e9curit\u00e9 \u00e0 laquelle on peut l\u00e9gitimement s&#8217;attendre \u00bb<\/a> (A product is defective within the meaning of this chapter where it does not provide the safety which a person is entitled to expect). A batch of antihypertensive tablets that fails the dissolution specifications, and therefore may leave hypertension uncontrolled, does not provide the safety a patient is entitled to expect from a blood pressure medicine; the FDA recall file, which identifies the batch, the specification failed and the number of bottles, is precisely the kind of official document on which a French court can rely to characterise that defect. The European origin of the rule reinforces the analysis, since Article 1 of Directive 85\/374\/EEC on liability for defective products (CELEX:31985L0374) makes the producer \u00ab responsable du dommage caus\u00e9 par un d\u00e9faut \u00bb (liable for damage caused by a defect) in his product, and Article 6 of the same directive defines the defect by reference to the safety legitimately expected in all the circumstances, including the presentation of the product, its reasonably expected use and the time when it was put into circulation.<\/p>\n<p>Two European judgments make this regime genuinely accessible to patients, including in cases where science cannot yet give a definitive answer. In a 2015 ruling on pacemakers and defibrillators presenting a potential failure risk, the Court of Justice held (CJUE, 5 March 2015, joined cases C-503\/13 and C-504\/13, Boston Scientific, CELEX:62013CJ0503) that a finding of \u00ab produits appartenant au m\u00eame groupe \u00bb (potential defect in products belonging to the same group) allows such a product to be classified as defective without needing to establish that defect in that individual product. Transposed to medicines, the reasoning means that once a batch is officially recalled for a proven manufacturing failure, each box of that batch can be treated as defective without the patient having to commission a laboratory analysis of their own tablets. In a 2017 ruling on a vaccine alleged to have caused multiple sclerosis, the Court went further on proof: it accepted (CJUE, 21 June 2017, case C-621\/15, W and Others v Sanofi Pasteur, CELEX:62015CJ0621) that certain facts relied on by the claimant may constitute \u00ab indices graves, pr\u00e9cis et concordants \u00bb (serious, specific and consistent presumptions) of both the defect and the causal link, even where medical research neither establishes nor rules out the link. A patient who shows the official recall of their batch, a documented period of use, home blood pressure readings that deteriorated during that period and a cardiovascular event that followed, therefore presents exactly the kind of serious, specific and consistent body of presumptions that European law allows judges to accept.<\/p>\n<p>French case law on defective medicines confirms each link of that chain, through three of the largest health scandals of recent decades. In the D\u00e9pakine litigation, where children exposed in utero to sodium valproate were born with malformations, the First Civil Chamber of the Cour de cassation recalled, in its ruling of 27 November 2019 (appeal 18-16.537), that <a href=\"https:\/\/www.courdecassation.fr\/decision\/5fca61cbeb012b49a0aa0420\">\u00ab un produit est d\u00e9fectueux lorsqu&#8217;il n&#8217;offre pas la s\u00e9curit\u00e9 \u00e0 laquelle on peut l\u00e9gitimement s&#8217;attendre et dans l&#8217;appr\u00e9ciation de la s\u00e9curit\u00e9 \u00e0 laquelle on peut l\u00e9gitimement s&#8217;attendre, il doit \u00eatre tenu compte de toutes les circonstances et notamment de la pr\u00e9sentation du produit \u00bb<\/a> (a product is defective where it does not provide the safety which a person is entitled to expect, and in assessing the safety which a person is entitled to expect, account must be taken of all the circumstances, including the presentation of the product). The same ruling fixed the starting point of the limitation period in terms that protect patients who discover the truth late: <a href=\"https:\/\/www.courdecassation.fr\/decision\/5fca61cbeb012b49a0aa0420\">\u00ab l&#8217;action en r\u00e9paration [&#8230;] se prescrit dans un d\u00e9lai de trois ans \u00e0 compter de la date \u00e0 laquelle le demandeur a eu ou aurait d\u00fb avoir connaissance du dommage, du d\u00e9faut et de l&#8217;identit\u00e9 du producteur \u00bb<\/a> (the action for compensation is time-barred three years from the date on which the claimant knew or should have known of the damage, the defect and the identity of the producer). The statutory version of that rule is Article 1245-16 of the Civil Code: <a href=\"https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000032023659\">\u00ab L&#8217;action en r\u00e9paration fond\u00e9e sur les dispositions du pr\u00e9sent chapitre se prescrit dans un d\u00e9lai de trois ans \u00e0 compter de la date \u00e0 laquelle le demandeur a eu ou aurait d\u00fb avoir connaissance du dommage, du d\u00e9faut et de l&#8217;identit\u00e9 du producteur \u00bb<\/a> (An action for compensation based on this chapter is time-barred three years from the date on which the claimant knew or should have known of the damage, the defect and the identity of the producer). Concretely, a patient who learns in September 2026, through the FDA recall, that the tablets taken months earlier belonged to a defective batch sees the clock start when they actually connect the damage, the defect and the manufacturer, not on the day they swallowed the first tablet. The detailed French-law path for the most serious cases, including proof and full compensation through the national compensation office (Office national d&#8217;indemnisation des accidents m\u00e9dicaux, ONIAM), is <a href=\"https:\/\/kohenavocats.com\/depakine-grossesse-enfant-handicape-prouver-indemnisation-integrale-2026\/\">explained step by step in the firm&#8217;s analysis of the D\u00e9pakine rulings<\/a>.<\/p>\n<p>In the Distilb\u00e8ne litigation, where daughters exposed in utero to diethylstilbestrol developed infertility and cancer risks decades later, the Cour de cassation added two holdings that matter directly for patients exposed to a defective batch without yet knowing the full consequences. In its ruling of 18 October 2023 (appeal 22-11.492) against the producer, the Court stated that <a href=\"https:\/\/www.courdecassation.fr\/decision\/652f768cb0532083189957de\">\u00ab ouvre droit \u00e0 r\u00e9paration le dommage en lien causal avec une faute, m\u00eame si celle-ci n&#8217;en est pas la seule cause \u00bb<\/a> (damage causally linked to a fault gives rise to compensation even if the fault is not its sole cause), which means a laboratory cannot escape by pointing to concurrent risk factors such as age, smoking or family history when the defective medicine contributed to the outcome. The same ruling recognised that <a href=\"https:\/\/www.courdecassation.fr\/decision\/652f768cb0532083189957de\">\u00ab constitue un pr\u00e9judice indemnisable l&#8217;anxi\u00e9t\u00e9 r\u00e9sultant de l&#8217;exposition \u00e0 un risque de dommage \u00bb<\/a> (anxiety resulting from exposure to a risk of damage constitutes compensable harm). A patient who learns they swallowed months of under-dosed antihypertensive tablets, and who must now undergo cardiac and neurological check-ups while waiting to know whether silent damage occurred, suffers exactly that kind of anxiety harm, compensable independently of any proven physical injury. The defendant is, in principle, the producer, and French courts accept jurisdiction when the damage occurred in France or the defective product was used there, even if the manufacturer sits abroad; the ANSM, for its part, can restrict or suspend the marketing of a product family on the French market under Article L. 5312-1 of the Code de la sant\u00e9 publique, which provides that <a href=\"https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000025104332\">\u00ab L&#8217;Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 peut soumettre \u00e0 des conditions particuli\u00e8res, restreindre ou suspendre [&#8230;] la mise sur le march\u00e9 \u00e0 titre gratuit ou on\u00e9reux [&#8230;] d&#8217;un produit ou groupe de produits \u00bb<\/a> (The national agency for the safety of medicines and health products may impose special conditions on, restrict or suspend the free or paid marketing of a product or group of products). Only a judge decides, in the end, whether the defect caused the harm claimed and what it is worth; no article, and no recall notice, can replace that individual assessment.<\/p>\n<h2>Conclusion<\/h2>\n<p>The chlorthalidone recall shaking the United States this week concerns identified American bottles, batch RISA24002, and it establishes no victim and no liability at this stage. For a reader in France, it calls for three calm reflexes: check the box and its batch number against the FDA file and the ANSM pages, never interrupt the treatment without the prescribing doctor, and file a report while keeping every piece of evidence. If harm followed the use of a defective batch, French and European law offer a complete path, from the producer&#8217;s strict liability under Article 1245 of the Civil Code to the three-year limitation period, the presumptions accepted by the Court of Justice, and the anxiety harm recognised by the Cour de cassation. The recall notice opens the file; the patient&#8217;s documents and the judge&#8217;s assessment decide the outcome.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA recalled 13,567 bottles of chlorthalidone 25 mg tablets for dissolution failure. The same molecule is sold in France: how to check your box, file a report, and claim compensation.<\/p>\n","protected":false},"author":232070755,"featured_media":4910,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kj_source_type":"","_kj_official_id":"","_kj_official_url":"","_kj_judilibre_id":"","_kj_jur":"","_kj_lieu":"","_kj_chambre":"","_kj_rg":"","_kj_date":"","footnotes":""},"categories":[7096,301720,384203],"tags":[],"class_list":["post-2229753","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-code-des-assurances","category-decryptage","category-droit-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France\" \/>\n<meta property=\"og:description\" content=\"The FDA recalled 13,567 bottles of chlorthalidone 25 mg tablets for dissolution failure. The same molecule is sold in France: how to check your box, file a report, and claim compensation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Hassan KOHEN\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-29T13:41:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-29T14:22:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kohenavocats.com\/wp-content\/uploads\/2024\/08\/chris-karidis-QSRSgWlAFCQ-unsplash.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"5858\" \/>\n\t<meta property=\"og:image:height\" content=\"3295\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Kohen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kohen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"18 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/\"},\"author\":{\"name\":\"Kohen\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#\\\/schema\\\/person\\\/761c9ba54fa1ca84d405cef0831ff751\"},\"headline\":\"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France\",\"datePublished\":\"2026-09-29T13:41:41+00:00\",\"dateModified\":\"2026-09-29T14:22:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/\"},\"wordCount\":3564,\"publisher\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/chris-karidis-QSRSgWlAFCQ-unsplash.webp\",\"articleSection\":[\"Code des assurances\",\"D\u00e9cryptage\",\"Droit m\u00e9dical\"],\"inLanguage\":\"en-US\",\"citation\":\"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France\",\"about\":[{\"@type\":\"Thing\",\"name\":\"Code des assurances\"},{\"@type\":\"Thing\",\"name\":\"D\u00e9cryptage\"},{\"@type\":\"Thing\",\"name\":\"Droit m\u00e9dical\"}],\"speakable\":{\"@type\":\"SpeakableSpecification\",\"cssSelector\":[\".article-content > p:first-of-type\"]}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/\",\"url\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/\",\"name\":\"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/chris-karidis-QSRSgWlAFCQ-unsplash.webp\",\"datePublished\":\"2026-09-29T13:41:41+00:00\",\"dateModified\":\"2026-09-29T14:22:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/chris-karidis-QSRSgWlAFCQ-unsplash.webp\",\"contentUrl\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2024\\\/08\\\/chris-karidis-QSRSgWlAFCQ-unsplash.webp\",\"width\":5858,\"height\":3295},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/\",\"name\":\"Hassan KOHEN\",\"description\":\"Ma\u00eetre Hassan Kohen, avocat p\u00e9naliste \u00e0 Paris, intervient exclusivement en droit p\u00e9nal pour la d\u00e9fense des particuliers, notamment en mati\u00e8re d\u2019accusations de viol. Il assure un accompagnement rigoureux d\u00e8s la garde \u00e0 vue jusqu\u2019\u00e0 la Cour d\u2019assises, veillant au strict respect des garanties proc\u00e9durales.\",\"publisher\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#organization\",\"name\":\"Hassan KOHEN\",\"url\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Logo-2-1.webp\",\"contentUrl\":\"https:\\\/\\\/kohenavocats.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Logo-2-1.webp\",\"width\":2114,\"height\":1253,\"caption\":\"Hassan KOHEN\"},\"image\":{\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/#\\\/schema\\\/person\\\/761c9ba54fa1ca84d405cef0831ff751\",\"name\":\"Kohen\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g\",\"caption\":\"Kohen\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/hassan-kohen-448548192\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@Kohen-Avocats\"],\"url\":\"https:\\\/\\\/kohenavocats.com\\\/en\\\/author\\\/kohenmlk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/","og_locale":"en_US","og_type":"article","og_title":"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France","og_description":"The FDA recalled 13,567 bottles of chlorthalidone 25 mg tablets for dissolution failure. The same molecule is sold in France: how to check your box, file a report, and claim compensation.","og_url":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/","og_site_name":"Hassan KOHEN","article_published_time":"2026-09-29T13:41:41+00:00","article_modified_time":"2026-09-29T14:22:02+00:00","og_image":[{"width":5858,"height":3295,"url":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2024\/08\/chris-karidis-QSRSgWlAFCQ-unsplash.webp","type":"image\/webp"}],"author":"Kohen","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Kohen","Est. reading time":"18 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/#article","isPartOf":{"@id":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/"},"author":{"name":"Kohen","@id":"https:\/\/kohenavocats.com\/en\/#\/schema\/person\/761c9ba54fa1ca84d405cef0831ff751"},"headline":"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France","datePublished":"2026-09-29T13:41:41+00:00","dateModified":"2026-09-29T14:22:02+00:00","mainEntityOfPage":{"@id":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/"},"wordCount":3564,"publisher":{"@id":"https:\/\/kohenavocats.com\/en\/#organization"},"image":{"@id":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2024\/08\/chris-karidis-QSRSgWlAFCQ-unsplash.webp","articleSection":["Code des assurances","D\u00e9cryptage","Droit m\u00e9dical"],"inLanguage":"en-US","citation":"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France","about":[{"@type":"Thing","name":"Code des assurances"},{"@type":"Thing","name":"D\u00e9cryptage"},{"@type":"Thing","name":"Droit m\u00e9dical"}],"speakable":{"@type":"SpeakableSpecification","cssSelector":[".article-content > p:first-of-type"]}},{"@type":"WebPage","@id":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/","url":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/","name":"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France","isPartOf":{"@id":"https:\/\/kohenavocats.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/#primaryimage"},"image":{"@id":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2024\/08\/chris-karidis-QSRSgWlAFCQ-unsplash.webp","datePublished":"2026-09-29T13:41:41+00:00","dateModified":"2026-09-29T14:22:02+00:00","breadcrumb":{"@id":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/#primaryimage","url":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2024\/08\/chris-karidis-QSRSgWlAFCQ-unsplash.webp","contentUrl":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2024\/08\/chris-karidis-QSRSgWlAFCQ-unsplash.webp","width":5858,"height":3295},{"@type":"BreadcrumbList","@id":"https:\/\/kohenavocats.com\/en\/blood-pressure-medication-recall-chlorthalidone-fda-rights-france-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/kohenavocats.com\/en\/"},{"@type":"ListItem","position":2,"name":"Blood Pressure Medication Recall: FDA Recalls Chlorthalidone Tablets, Your Rights in France"}]},{"@type":"WebSite","@id":"https:\/\/kohenavocats.com\/en\/#website","url":"https:\/\/kohenavocats.com\/en\/","name":"Hassan KOHEN","description":"Ma\u00eetre Hassan Kohen, avocat p\u00e9naliste \u00e0 Paris, intervient exclusivement en droit p\u00e9nal pour la d\u00e9fense des particuliers, notamment en mati\u00e8re d\u2019accusations de viol. Il assure un accompagnement rigoureux d\u00e8s la garde \u00e0 vue jusqu\u2019\u00e0 la Cour d\u2019assises, veillant au strict respect des garanties proc\u00e9durales.","publisher":{"@id":"https:\/\/kohenavocats.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kohenavocats.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kohenavocats.com\/en\/#organization","name":"Hassan KOHEN","url":"https:\/\/kohenavocats.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kohenavocats.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2026\/01\/Logo-2-1.webp","contentUrl":"https:\/\/kohenavocats.com\/wp-content\/uploads\/2026\/01\/Logo-2-1.webp","width":2114,"height":1253,"caption":"Hassan KOHEN"},"image":{"@id":"https:\/\/kohenavocats.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/kohenavocats.com\/en\/#\/schema\/person\/761c9ba54fa1ca84d405cef0831ff751","name":"Kohen","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1c5e76ef76bbbfdd2b4da984e2bf2fa4056fd51a27d25ce2c332047f1dfd6e00?s=96&d=identicon&r=g","caption":"Kohen"},"sameAs":["https:\/\/www.linkedin.com\/in\/hassan-kohen-448548192\/","https:\/\/www.youtube.com\/@Kohen-Avocats"],"url":"https:\/\/kohenavocats.com\/en\/author\/kohenmlk\/"}]}},"_links":{"self":[{"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/posts\/2229753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/users\/232070755"}],"replies":[{"embeddable":true,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/comments?post=2229753"}],"version-history":[{"count":1,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/posts\/2229753\/revisions"}],"predecessor-version":[{"id":2230149,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/posts\/2229753\/revisions\/2230149"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/media\/4910"}],"wp:attachment":[{"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/media?parent=2229753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/categories?post=2229753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kohenavocats.com\/en\/wp-json\/wp\/v2\/tags?post=2229753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}